Stockreport

CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update

CorMedix Inc.  (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
PDF ? Q3 2024 Net Revenue of $11.5 million ? ? Commercializing DefenCath with Four of Top Five US Dialysis Providers ? ? Conference Call Scheduled for Today at 8:30 a.m. E [Read more]